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Background: BCR-ABL1 negative chronic myeloproliferative neoplasms (CMPNs) are 
a heterogeneous group of clonal hematological malignancies. In last years, some 
genetic alterations have been described to cause these diseases, most of them activating 
tyrosine kinase (TK) genes. Tyrosine kinases proteins have an important role in cell 
growth and oncogenesis. Gain-of-function mutations in TK genes can produce a 
constitutive activation of several signaling pathways.  
Aims: In this study, we study the EGFR gene that codes for a tyrosine kinase receptor 
(RTK) involved in signaling pathways relevant in hematological cells. Mutations in this 
gene have been found involved in lung cancer, and it could have an important role in 
the pathogenesis of hematological disorders.  
Methods: We have analyzed the transmembrane and TK-coding domains of EGFR by 
dHPLC to detect mutations on samples from 44 BCR-ABL1 negative / V617FJAK2 
negative CMPN patients and 20 control samples from healthy individuals. 
Results: Our results show that this gene is not frequently mutated in CMPNs.  
Conclusion: The EGF Receptor gene does not appear to be involved in the 
pathogenesis of the myeloproliferative neoplasms.  
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